Clinical Trials Logo

Nosebleeds clinical trials

View clinical trials related to Nosebleeds.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01406639 Withdrawn - Clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT)

Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT as measured by the HHT Epistaxis Severity Score (ESS), hematocrit, and hemoglobin and serum ferritin levels.